6WJ5 | pdb_00006wj5

Structure of human TRPA1 in complex with inhibitor GDC-0334

• PDB DOI: https://doi.org/10.2210/pdb6WJ5/pdb
• EM Map EMD-21688: EMDB EMDataResource

• Classification: MEMBRANE PROTEIN/Inhibitor
• Organism(s): Homo sapiens
• Expression System: Spodoptera frugiperda
• Mutation(s): No 
• Membrane Protein: Yes  OPMPDBTMMemProtMD


• Deposited: 2020-04-11 Released: 2021-02-17 
• Deposition Author(s): Rohou, A., Rouge, L., Arthur, C.P., Volgraf, M., Chen, H.

---

Experimental Data Snapshot

• Method: ELECTRON MICROSCOPY
• Resolution: 3.60 Å
• Aggregation State: PARTICLE 
• Reconstruction Method: SINGLE PARTICLE 

Starting Model: experimental

Literature

A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment.

Balestrini, A., Joseph, V., Dourado, M., Reese, R.M., Shields, S.D., Rouge, L., Bravo, D.D., Chernov-Rogan, T., Austin, C.D., Chen, H., Wang, L., Villemure, E., Shore, D.G.M., Verma, V.A., Hu, B., Chen, Y., Leong, L., Bjornson, C., Hotzel, K., Gogineni, A., Lee, W.P., Suto, E., Wu, X., Liu, J., Zhang, J., Gandham, V., Wang, J., Payandeh, J., Ciferri, C., Estevez, A., Arthur, C.P., Kortmann, J., Wong, R.L., Heredia, J.E., Doerr, J., Jung, M., Vander Heiden, J.A., Roose-Girma, M., Tam, L., Barck, K.H., Carano, R.A.D., Ding, H.T., Brillantes, B., Tam, C., Yang, X., Gao, S.S., Ly, J.Q., Liu, L., Chen, L., Liederer, B.M., Lin, J.H., Magnuson, S., Chen, J., Hackos, D.H., Elstrott, J., Rohou, A., Safina, B.S., Volgraf, M., Bauer, R.N., Riol-Blanco, L.

(2021) J Exp Medicine 218

• PubMed: 33620419 
• DOI: https://doi.org/10.1084/jem.20201637
• Primary Citation Related Structures: 
  6WJ5


• PubMed Abstract: 
  

  Despite the development of effective therapies, a substantial proportion of asthmatics continue to have uncontrolled symptoms, airflow limitation, and exacerbations. Transient receptor potential cation channel member A1 (TRPA1) agonists are elevated in human asthmatic airways, and in rodents, TRPA1 is involved in the induction of airway inflammation and hyperreactivity. Here, the discovery and early clinical development of GDC-0334, a highly potent, selective, and orally bioavailable TRPA1 antagonist, is described. GDC-0334 inhibited TRPA1 function on airway smooth muscle and sensory neurons, decreasing edema, dermal blood flow (DBF), cough, and allergic airway inflammation in several preclinical species. In a healthy volunteer Phase 1 study, treatment with GDC-0334 reduced TRPA1 agonist-induced DBF, pain, and itch, demonstrating GDC-0334 target engagement in humans. These data provide therapeutic rationale for evaluating TRPA1 inhibition as a clinical therapy for asthma.

---

Organizational Affiliation: 
• Department of Immunology Discovery, Genentech, Inc., South San Francisco, CA.
Department of Biomedical Imaging, Genentech, Inc., South San Francisco, CA.
Department of Neuroscience, Genentech, Inc., South San Francisco, CA.
Department of Structural Biology, Genentech, Inc., South San Francisco, CA.
Department of Biochemical and Cellular Pharmacology, Genentech, Inc., South San Francisco, CA.
Department of Pathology, Genentech, Inc., South San Francisco, CA.
Department of Discovery Chemistry, Genentech, Inc., South San Francisco, CA.
Pharmaron-Beijing Co. Ltd., BDA, Beijing, People's Republic of China.
Department of Translational Immunology, Genentech, Inc., South San Francisco, CA.
Department of Molecular Biology, Genentech, Inc., South San Francisco, CA.
Department of OMNI Bioinformatics, Genentech, Inc., South San Francisco, CA.
Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, CA.
Department of Biomolecular Resources, Genentech, Inc., South San Francisco, CA.
Department of Product Development Biometric Biostatistics, Genentech, Inc., South San Francisco, CA.
Department of Clinical Imaging, Genentech, Inc., South San Francisco, CA.
Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA.
Department of Early Clinical Development, Genentech, Inc., South San Francisco, CA.
Department of OMNI-Biomarker Development, Genentech, Inc., South San Francisco, CA.

Biological Assembly 1  

Global Symmetry: Cyclic - C4  (Explore in 3D)
Global Stoichiometry: Homo 4-mer - A4 

Biological assembly 1 assigned by authors.

Macromolecule Content 

• Total Structure Weight: 292.93 kDa 
• Atom Count: 18,052 
• Modeled Residue Count: 2,248 
• Deposited Residue Count: 2,524 
• Unique protein chains: 1

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Transient receptor potential cation channel subfamily A member 1	A, B, C, D	631	Homo sapiens	Mutation(s): 0  Gene Names: TRPA1, ANKTM1 Membrane Entity: Yes
UniProt & NIH Common Fund Data Resources
Find proteins for O75762 (Homo sapiens) Explore O75762  Go to UniProtKB:  O75762
PHAROS:  O75762 GTEx:  ENSG00000104321

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
LXY (Subject of Investigation/LOI)	E [auth A], F [auth B], G [auth C], H [auth D]	(4R,5S)-4-fluoro-1-[(4-fluorophenyl)sulfonyl]-5-methyl-N-({5-(trifluoromethyl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]pyridin-4-yl}methyl)-L-prolinamide C24 H19 F8 N5 O3 S RGXNECXVRZKGGH-UOXRKKOCSA-N

Experimental Data & Validation

Experimental Data

• Method: ELECTRON MICROSCOPY
• Resolution: 3.60 Å
• Aggregation State: PARTICLE 
• Reconstruction Method: SINGLE PARTICLE 

EM Software:

Task	Software Package	Version
RECONSTRUCTION	cisTEM
MODEL REFINEMENT	PHENIX

Structure Validation

Entry History 

Deposition Data

• Released Date: 2021-02-17 
Deposition Author(s): Rohou, A., Rouge, L., Arthur, C.P., Volgraf, M., Chen, H.

Revision History  

• Version 1.0: 2021-02-17
  Type: Initial release
  
• Version 1.1: 2021-08-04
  Changes: Database references
• Version 1.2: 2021-08-11
  Changes: Database references
• Version 1.3: 2024-05-29
  Changes: Data collection, Refinement description